ArticleMolecular therapy. Methods & clinical development2025

Preclinical development of TAK-754, a high-performance AAV8-based vector expressing coagulation factor VIII.

Johannes Lengler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.